Rapid Identification of Dihydropyrimidine Dehydrogenase Deficiency by Using A Novel 2-13C-Uracil Breath Test

Clinical Cancer Research

Volumn 10, Issue 8, 2004, Pages 2652-2658

  Mattison, Lori K ^a   Ezzeldin, Hany ^a   Carpenter, Mark ^b,d   Modak, Anil ^c   Johnson, Martin R ^a   Diasio, Robert B ^a,e  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Department of Pharmacology and Toxicology and Mass Spectrometry Core Facility   (United States)

^c CAMBRIDGE ISOTOPE LABORATORIES INC   (United States)

^d AUBURN UNIVERSITY   (United States)

^e University of Alabama School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 13; DIHYDROPYRIMIDINE DEHYDROGENASE; URACIL;

ADULT; AQUEOUS SOLUTION; ARTICLE; BREATH ANALYSIS; CANCER PATIENT; CARBON DIOXIDE MEASUREMENT; CLINICAL ARTICLE; CLINICAL PRACTICE; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY; ENZYME ACTIVITY; ENZYME DEFICIENCY; EXHALATION; FEMALE; GENOTYPE; HUMAN; INFRARED SPECTROSCOPY; MALE; PRIORITY JOURNAL; RADIOASSAY; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; URACIL BREATH TEST;

ANTIMETABOLITES, ANTINEOPLASTIC; BREATH TESTS; CARBON DIOXIDE; CARBON ISOTOPES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIAGNOSTIC TESTS, ROUTINE; DIHYDROURACIL DEHYDROGENASE (NADP); FLUOROURACIL; GENOTYPE; HUMANS; PHENOTYPE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TIME FACTORS; URACIL;

EID: 1942502420     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0374     Document Type: Article

References (37)

1. Johnson MR, Wang K, Diasio RB. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin Cancer Res 2002;8:768-74.
2. Mattison LK, Johnson MR, Diasio RB. A comparative analysis of translated dihydropyrimidine dehydrogenase cDNA; conservation of functional domains and relevance to genetic polymorphisms. Pharmacogenetics 2002;12:133-44.
3. Johnson MR, Diasio RB. Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. Adv Enzyme Regul 2001;41:151-7.
4. Van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation. Int J Cancer 2002;101:253-8.
5. Lu Z, Zhang R, Diasio RB. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 1993;53:5433-8.
6. Lu Z, Zhang R, Carpenter JT, Diasio RB. Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy. Clin Cancer Res 1998;4:325-9.
7. Etienne MC, Lagrange JL, Dassonville O, et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 1994;12:2248-53.
8. Johnson MR, Yan J, Shao L, Albin N, Diasio RB. Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity. J Chromatogr B Biomed Sci Appl 1997;696:183-91.
9. Kuhara T, Ohdoi C, Ohse M. Simple gas chromatographic-mass spectrometric procedure for diagnosing pyrimidine degradation defects for prevention of severe anticancer side effects. J Chromatogr B Biomed Sci Appl 2001;758:61-74.
10. Fernandez-Salguero P, Gonzalez FJ, Etienne MC, Milano G, Kimura S. Correlation between catalytic activity and protein content for the polymorphically expressed dihydropyrimidine dehydrogenase in human lymphocytes. Biochem Pharmacol 1995;50:1015-20.
11. Ezzeldin H, Okamoto Y, Johnson MR, Diasio RB. A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency. Anal Biochem 2002;306:63-73.
12. 2 breath test. Gastroenterology 1989;96:503-9.
13. 13C mixed triglyceride breath test: a noninvasive method to assess lipase activity in children. J Pediatr Gastroenterol Nutr 2001;32:579-85.
14. 13C-egg white breath test: a non-invasive test of pancreatic trypsin activity in the small intestine. Gut 2000;46:52-7.
15. Forne M, Dominguez J, Fernandez-Banares F, et al. Accuracy of an enzyme immunoassay for the detection of Helicobacter pylori in stool specimens in the diagnosis of infection and posttreatment check-up. Am J Gastroenterol 2000;95:2200-5.
16. Shepherd AJ, Doherty CP, Weaver LT, et al. Comparison of an enzyme immunoassay for the detection of Helicobacter pylori antigens in the faeces with the urea breath test. Arch Dis Child 2000;83:268-70.
17. 2 urea breath analyzer instruction manual. Lafayette, CO: Meretek Diagnostics; 2002. p. A1-A2.
18. 13C-breath tests to measure fat and carbohydrate digestion in clinical practice. Clin Nutr 1995;14:149-54.
19. Harris BE, Song R, Soong SJ, Diasio RB. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990;50:197-201.
20. Phillips KF. Power of the two one-sided tests procedure in bioequivalence. J Pharmacokinet Biopharm 1990;18:137-44.
21. Diletti E, Hauschke D, Steinijans VW. Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol 1991;29:1-8.
22. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200-5.
23. Scrip's Cancer Chemotherapy Report. Scrip World Pharmaceutical News. London: PJB Publications Ltd., 2002.
24. Meta-Analysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 1998;16:3537-41.
25. van Kuilenburg AB, Haasjes J, Richel DJ, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 2000;6:4705-12.
26. Diasio RB, Beavers TL, Carpenter JT. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Investig 1988;81:47-51.
27. Heslin MJ, Yan J, Weiss H, et al. Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer. Cancer Chemother Pharmacol 2003;52:399-404.
28. Naguib FN, el Kouni MH, Cha S. Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 1985;45:5405-12.
29. Spector T, Harrington JA, Porter DJ. 5-Ethynyluracil (776C85): inactivation of dihydropyrimidine dehydrogenase in vivo. Biochem Pharmacol 1993;46:2243-8.
30. Ezzeldin H, Johnson MR, Okamoto Y, Diasio R. Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity. Clin Cancer Res 2003;9:3021-8.
31. Johnson MR, Hageboutros A, Wang K, High L, Smith JB, Diasio RB. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res 1999;5:2006-11.
32. Meinsma R, Fernandez-Salguero P, Van Kuilenburg AB, Van Gennip AH, Gonzalez FJ. Human polymorphism in drug metabolism: mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uracilurea. DNA Cell Biol 1995;14:1-6.
33. Collie-Duguid ES, Etienne MC, Milano G, McLeod HL. Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics 2000;10:217-23.
34. Sumi S, Imaeda M, Kidouchi K, et al. Population and family studies of dihydropyrimidinuria: prevalence, inheritance mode, and risk of fluorouracil toxicity. Am J Med Genet 1998;78:336-40.
35. van Kuilenburg AB, Meinsma R, Zonnenberg BA, et al. Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity. Clin Cancer Res 2003;9:4363-7.
36. Ohse M, Matsuo M, Ishida A, Kuhara T. Screening and diagnosis of beta-ureidopropionase deficiency by gas chromatographic/mass spectrometric analysis of urine. J Mass Spectrom 2002;37:954-62.
37. Pullarkat ST, Stoehlmacher J, Ghaderi V, et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 2001;1:65-70.